Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

AZN

Astrazeneca plc ADR

Oct 04 • 04:00PM ET

77.47

Dollar change -0.46
Percentage change -0.59	%

Healthcare • Drug Manufacturers - General • United Kingdom • NASD

Held by: QQQ QQQM FVD PPH DFIC AVDE DIHP TQQQ QYLD QQEW

Scroll to Statements

Index	NDX	P/E	37.54	EPS (ttm)	2.06	Insider Own	0.03%	Shs Outstand	3.10B	Perf Week	-0.19%
Market Cap	240.20B	Forward P/E	16.31	EPS next Y	4.75	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	-6.66%
Income	6.44B	PEG	2.99	EPS next Q	1.05	Inst Own	16.27%	Short Float	0.21%	Perf Quarter	0.44%
Sales	49.13B	P/S	4.89	EPS this Y	13.31%	Inst Trans	-0.70%	Short Ratio	1.42	Perf Half Y	14.86%
Book/sh	12.74	P/B	6.08	EPS next Y	15.51%	ROA	6.41%	Short Interest	6.45M	Perf Year	16.29%
Cash/sh	2.28	P/C	33.95	EPS next 5Y	12.57%	ROE	16.75%	52W Range	60.47 - 87.68	Perf YTD	15.03%
Dividend Est.	1.55 (2.01%)	P/FCF	24.56	EPS past 5Y	17.72%	ROI	9.51%	52W High	-11.64%	Beta	0.47
Dividend TTM	1.49 (1.92%)	Quick Ratio	0.69	Sales past 5Y	16.24%	Gross Margin	74.22%	52W Low	28.11%	ATR (14)	1.18
Dividend Ex-Date	Aug 09, 2024	Current Ratio	0.89	EPS Y/Y TTM	4.49%	Oper. Margin	19.09%	RSI (14)	38.71	Volatility	1.10% 1.35%
Employees	89900	Debt/Eq	0.85	Sales Y/Y TTM	10.45%	Profit Margin	13.11%	Recom	1.83	Target Price	92.42
Option/Short	Yes / Yes	LT Debt/Eq	0.71	EPS Q/Q	5.99%	Payout	73.87%	Rel Volume	1.14	Prev Close	77.93
Sales Surprise	2.48%	EPS Surprise	0.74%	Sales Q/Q	13.33%	Earnings	Jul 25 BMO	Avg Volume	4.53M	Price	77.47
SMA20	-1.80%	SMA50	-4.89%	SMA200	4.84%	Trades		Volume	5,184,313	Change	-0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy	$75
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold

Show Previous Ratings

Oct-04-24 06:34AM	FDA grants priority review for AstraZeneca's Calquence sNDA (Pharmaceutical Business Review)
Oct-03-24 02:09PM	AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review (Benzinga)
07:00AM	CALQUENCE (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma (Business Wire)
06:52AM	Owkin and AstraZeneca to develop AI tool for breast cancer testing (Medical Device Network)
04:32AM	Arcus and AstraZeneca enter trial collaboration for renal cancer treatment (Clinical Trials Arena)
04:05PM	Loading…
Oct-02-24 04:05PM	Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma (Business Wire)
Oct-01-24 07:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy (Business Wire)
05:00AM	5 FDA decisions to watch in the fourth quarter (BioPharma Dive)
02:00AM	ENHERTU Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy (Business Wire)
Sep-30-24 12:30PM	AstraZeneca (AZN): A Strong Buy as FDA Approves Key Cancer Treatments and Revenue Surges (Insider Monkey)
10:22AM	Is AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now? (Insider Monkey)
Sep-29-24 02:07AM	Is AstraZeneca PLC (AZN) the Best Cheap Growth Stock to Buy According to Analysts? (Insider Monkey)
Sep-28-24 01:06PM	15 Unhealthiest Countries in Europe (Insider Monkey)
Sep-27-24 08:53AM	US first self-administered flu vaccine could increase accessibility and uptake (Clinical Trials Arena)
05:00AM	ANGLE PLC (ANPCY) (Q2 2024) Earnings Call Transcript Highlights: Key Takeaways from the ... (GuruFocus.com)
04:32AM	Loading…
04:32AM	AstraZenecas Tagrisso gains FDA approval for stage III NSCLC (Pharmaceutical Technology)
Sep-26-24 11:19AM	AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication (Benzinga)
09:05AM	AstraZeneca in AI collaboration with Immunai to inform cancer drug trials (Reuters)
08:51AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
07:00AM	TAGRISSO (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer (Business Wire)
Sep-24-24 11:33PM	AstraZeneca PLC (AZN): A Risky Bet on Emerging Cancer Treatments (Insider Monkey)
06:12AM	EMA CHMP recommends AstraZenecas Fasenra to treat EGPA (Pharmaceutical Technology)
Sep-23-24 08:35PM	Is AstraZeneca PLC (AZN) the Best Growth Stock To Buy According To George Soros? (Insider Monkey)
04:06PM	AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug (Investor's Business Daily)
11:43AM	Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug (Benzinga)
10:57AM	AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial (Investopedia)
09:38AM	AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug (Investor's Business Daily)
08:48AM	Heres Why AstraZeneca PLC (AZN) Surged in Q2 (Insider Monkey)
08:11AM	AstraZeneca, Daiichis Enhertu successor faces more questions after latest stumble (BioPharma Dive)
07:45AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:44AM	Loading…
07:44AM	Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients (Benzinga)
07:00AM	Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial (Business Wire)
06:52AM	AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial (Clinical Trials Arena)
04:32AM	FDA approves AstraZeneca FluMist flu vaccine for self-administration (Pharmaceutical Technology)
Sep-20-24 06:15PM	Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
04:34PM	FLUMIST approved for self-administration in the US (Business Wire)
12:22PM	US FDA approves AstraZeneca's self-administered nasal spray flu vaccine (Reuters)
Sep-19-24 11:53AM	AstraZenecas Fasenra to challenge GSKs Nucala in rare vasculitis after FDA nod (Pharmaceutical Technology)
09:30AM	Wall Street Bulls Look Optimistic About Astrazeneca (AZN): Should You Buy? (Zacks)
09:13AM	AstraZenecas Fasenra meets primary endpoint in Phase III rare vasculitis trial (Clinical Trials Arena)
04:21AM	2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again (Motley Fool)
02:30AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-18-24 07:00AM	FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis (Business Wire)
12:35AM	Pfizer and AstraZeneca debate: when the greater good matters (The Accountant)
Sep-17-24 11:22AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
06:33AM	UK rollout of AZ/Oxford Covid-19 vaccine: what you need to know (Pharmaceutical Technology)
04:52AM	AstraZenecas Imfinzi and Imjudo found to extend survival in liver cancer trial (Clinical Trials Arena)
Sep-16-24 07:00AM	IMFINZI (durvalumab) plus IMJUDO (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial (Business Wire)
01:52AM	ASCO 2020: ADAURA trial demonstrates a 79% reduction in the risk of death with Tagrisso in the adjuvant setting (Clinical Trials Arena)
Sep-15-24 10:30AM	IMFINZI (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial (Business Wire)
Sep-13-24 10:15PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
10:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases (Business Wire)
06:09AM	AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls (Bloomberg)
Sep-12-24 02:50AM	BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma (ACCESSWIRE)
Sep-11-24 07:33AM	Sophia Genetics and AstraZeneca collaborate to expand liquid biopsy test rollout (Medical Device Network)
Sep-10-24 03:09PM	AstraZeneca PLC (AZN): Short Seller Sentiment For This Big-Name Stock is Bullish (Insider Monkey)
12:54PM	AstraZeneca/Daiichis ADC shows better survival for nonsquamous NSCLC patients (Pharmaceutical Technology)
12:03PM	AstraZeneca Faces Setback From Lung Cancer Drug's Disappointing Trial Results (Investopedia)
10:28AM	SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing (PR Newswire)
09:19AM	AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results (Benzinga)
08:16AM	AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial (Benzinga)
07:35AM	New data add to doubts about AstraZeneca, Daiichis Enhertu successor (BioPharma Dive)
07:15AM	5 Things to Know Before the Stock Market Opens (Investopedia)
06:53AM	AstraZeneca eyes up transition to eco-friendly inhaler propellant (Medical Device Network)
04:59AM	Stocks to Watch Tuesday: Apple, Oracle, Alibaba (The Wall Street Journal)
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga)
01:50PM	Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial (Business Wire)
01:00AM	Innate Pharma SA:Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024 (Business Wire)
Sep-08-24 12:25PM	Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial (Business Wire)
Sep-06-24 05:15AM	3 Market-Beating Stocks to Buy for Less Than $100 (Motley Fool)
Sep-05-24 02:56PM	AstraZeneca Employees Held in China for Data Privacy, Drug-Import Investigations (Investopedia)
02:56PM	AstraZeneca Employees Held in China for Drug-Import, Data Privacy Investigations (Investopedia)
01:37PM	AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities (Benzinga)
09:00AM	China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug (The Wall Street Journal)
04:50AM	AstraZeneca says small number of employees under investigation in China (Financial Times)
04:50AM	AstraZeneca staff detained in China amid claims of illegal drug imports (The Telegraph)
03:42AM	China Detains AstraZeneca Staff in Data, Drug-Import Probes (Bloomberg)
Sep-04-24 07:33AM	EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity (Benzinga)
Sep-03-24 11:32PM	Is AstraZeneca PLC (AZN) the Best Cancer Stock to Buy Now? (Insider Monkey)
07:00AM	AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024 (Business Wire)
01:08AM	Several Reasons for the Outperformance of Astrazeneca Plc (AZN) (Insider Monkey)
Sep-02-24 05:07PM	AstraZeneca PLC (AZN): A Good 52-Week High Stock to Buy According to Short Sellers (Insider Monkey)
Sep-01-24 10:08PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
Aug-31-24 02:52PM	Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis (Pharmaceutical Technology)
Aug-29-24 06:00AM	Qiagen, AstraZeneca expand companion diagnostic pact beyond cancer (MedTech Dive)
Aug-28-24 12:36PM	AstraZeneca PLC (AZN): A Cheap Pharmaceutical Stock to Buy According to Short Sellers (Insider Monkey)
Aug-26-24 11:18AM	AstraZeneca (AZN) Denies Rumors About UK Facility Relocation (Zacks)
Aug-23-24 12:23PM	AstraZeneca may pull plug on UK vaccine manufacturing plans (Pharmaceutical Technology)
08:39AM	AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support (Benzinga)
Aug-22-24 04:10PM	AstraZeneca warns of shifting UK vaccine production to US, FT reports (Reuters)
04:10PM	AstraZeneca warns of moving UK vaccine production to US, FT reports (Reuters)
04:10PM	AstraZeneca threatens to move UK vaccine production to US, FT reports (Reuters)
Aug-21-24 12:42AM	Covid-19: vaccine pricing varies wildly by country and company (Pharmaceutical Technology)
Aug-20-24 02:30PM	Heard Writers Pick Their Favorite and Least-Favorite Stocks (The Wall Street Journal)
07:53AM	J&J drug combo for lung cancer approved by FDA (BioPharma Dive)
07:00AM	AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus. (The Wall Street Journal)
Aug-19-24 07:42AM	EMA validates Type II Variation application for ENHERTU for breast cancer treatment (Pharmaceutical Business Review)
06:33AM	Daiichi Sankyo-AstraZenecas ENHERTU gains BTD for breast cancer (Pharmaceutical Technology)
Aug-17-24 08:09AM	AIM ImmunoTech Inc. (AMEX:AIM) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-16-24 01:21PM	How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise? (Zacks)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc ADR

Upgrade your FINVIZ experience